Allon Therapeutics confirms oral bioavailability of CNS drug AL-309
Allon Therapeutics Inc. released new data confirming that the Company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.
Gordon McCauley, President and CEO of Allon, said earlier preclinical studies demonstrated that AL-309 had neuroprotective effects in several animal models of neurodegenerative disease.
"These new results are quite significant as they show that AL-309 passes through two meaningful barriers to drug delivery: the intestinal wall and the blood-brain barrier (BBB). These characteristics are essential for an orally administered central nervous system drug and validate the Company's program to develop AL-309 as a treatment for neurodegenerative disease," McCauley said.
McCauley said AL-309 will be the first product to move into clinical development from the Company's second platform of neuroprotective compounds. AL-309 will complement development of AL-108 and AL-208, which are currently being evaluated in Phase II clinical trials as treatments for Alzheimer's disease and for mild cognitive impairment associated with coronary artery bypass graft surgery. A third Phase II trial will begin in mid-2007 to evaluate AL-108 as a treatment for schizophrenia-related cognitive impairment.
Other news from the department research and development
